Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
ZONSZEIN, Joel
LOMBARDERO, Manuel
ISMAIL-BEIGI, Faramarz
PALUMBO, Pasquale
FOUCHER, Suzy
GROENEWOUD, Yolanda
CUSHING, Gary
GENUTH, Saul
Citação
JOURNAL OF DIABETES RESEARCH, article ID 129891, 12p, 2015
Resumo
Glycemic management is central in prevention of small vessel and cardiovascular complications in type 2 diabetes. With the plethora of newer medications and recommendations for a patient centered approach, more information is necessary to match the proper drug to each patient. We showed that BARI 2D, a five-year trial designed to compare two different glycemic treatment strategies, was suitable for assessing different responses according to different phenotypic characteristics. Treatment with insulin sensitizing medications such as thiazolidinediones and metformin was more effective in improving glycemic control, particularly in the more insulin resistant patient, when compared to the insulin provision strategy using insulin and or sulfonylureas. Triglyceride and high density lipoprotein ratio (TG/HDL-cholesterol ratio) was found to be a readily available and practical biomarker that helps to identify the insulin resistant patient. These results support the concept that not all medications for glycemic control work the same in all patients. Thus, tailored therapy can be done using phenotypic characteristics rather than a ""one-size-fits-all approach.""
Palavras-chave
Referências
- American Diabetes Association, 2015, DIABETES CARE S1, V38, pS41, DOI 10.2337/dc15-S010
- Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3
- Brooks MM, 2008, AM HEART J, V156, P528, DOI 10.1016/j.ajh.2008.05.015
- Colhoun HM, 2012, DIABETOLOGIA, V55, P2929, DOI 10.1007/s00125-012-2668-0
- D'Adamo E, 2011, DIABETES CARE, V34, pS161, DOI 10.2337/dc11-s212
- DeFronzo RA, 2009, DIABETES, V58, P773, DOI 10.2337/db09-9028
- Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9
- Gidding SS, 1996, AM J CARDIOL, V78, P304, DOI 10.1016/S0002-9149(96)00282-2
- Gregg EW, 2014, NEW ENGL J MED, V370, P1514, DOI 10.1056/NEJMoa1310799
- Gross JL, 2011, ANN INTERN MED, V154, P672, DOI [10.7326/0003-4819-154-10-201105170-00007, 10.1059/0003-4819-154-10-201105170-00007]
- Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
- Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394
- Inzucchi SE, 2015, DIABETES CARE, V38, P140, DOI 10.2337/dc14-2441
- Ismail-Beigi F, 2014, J DIABETES COMPLICAT, V28, P101, DOI 10.1016/j.jdiacomp.2013.01.006
- Jeppesen J, 1998, J INTERN MED, V243, P293
- Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
- LAWS A, 1992, J INTERN MED, V231, P25
- Li CY, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-4
- Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180
- McLaughlin T, 2003, ANN INTERN MED, V139, P802
- McLaughlin T, 2005, AM J CARDIOL, V96, P399, DOI 10.1016/j.amjcard.2005.03.085
- Nathan DM, 2013, DIABETES CARE, V36, P2254, DOI 10.2337/dc13-0356
- Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
- Pinhas-Hamiel O, 2005, J PEDIATR-US, V146, P693, DOI 10.1016/j.jpeds.2004.12.042
- Rutter MK, 2010, DIABETES VASC DIS RE, V7, P69, DOI 10.1177/1479164109354145
- Shulman GI, 2014, NEW ENGL J MED, V371, P1131, DOI 10.1056/NEJMra1011035
- Smith RJ, 2010, J CLIN ENDOCR METAB, V95, P1566, DOI 10.1210/jc.2009-1966
- Sumner AE, 2008, ATHEROSCLEROSIS, V196, P696, DOI 10.1016/j.atherosclerosis.2006.12.018
- Sumner AE, 2005, ARCH INTERN MED, V165, P1395, DOI 10.1001/archinte.165.12.1395
- The Bypass Angioplasty Revascularization Investigation 2 Diabetes Investigators, 2009, NEW ENGLAND J MED, V360, P2503
- TURNER RC, 1995, DIABETES, V44, P1249